Yuling Luo, Ph.D.

Venture Partner

Yuling is a technologist and serial entrepreneur, and he has spent his entire career in life science startup companies. Yuling is currently the Founder, Chairman and CEO of Alamar Biosciences, a startup company developing game-changing technologies for early detection of cancer and other diseases.  He is the inventor of RNAscope, a breakthrough molecular detection technology that has become increasingly popular for life science research and diagnostics. As the Founder, President and CEO of Advanced Cell Diagnostics (ACD), he led the company from concept to successful product launch and commercialization. Under his leadership, ACD has become one of the fastest growing life science company, which was acquired by Bio-Techne for $325M in 2016. Yuling and his team have created $300M value for ACD shareholders. Before ACD, Yuling was a co-founder of Panomics (previously named Genospectra before its acquisition of Panomics), a life science company that was acquired by Affymetrix in 2008. At Panomics, he served various roles including Vice President, Functional Genomics and Chief Scientific Officer and he led the development and launch of all its flagship products. Prior to Panomics, Dr. Luo was one of the earliest senior scientists at Exelixis, now a NASDAQ company, where he led a team to identify and validate novel therapeutic targets. Yuling has published numerous research papers in top peer-reviewed journals. His inventions are the subject of over 30 issued patents. Yuling received a B.S. in Chemistry from the University of Science & Technology of China and earned a Ph.D. in Biochemistry from Case Western Reserve University.

Copyright 2018 IIF Management Company LLC.  All rights reserved.  “Illumina” and “Illumina Ventures” are trademarks of Illumina, Inc. and are used herein with their permission.  All other company names, logos, and other trademarks are the property of their respective owners.